Logo image of MRKR

MARKER THERAPEUTICS INC (MRKR) Stock Fundamental Analysis

NASDAQ:MRKR - Nasdaq - US57055L2060 - Common Stock - Currency: USD

1.275  -0.08 (-5.56%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MRKR. MRKR was compared to 551 industry peers in the Biotechnology industry. MRKR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MRKR shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MRKR had negative earnings in the past year.
In the past year MRKR has reported a negative cash flow from operations.
In the past 5 years MRKR always reported negative net income.
MRKR had a negative operating cash flow in each of the past 5 years.
MRKR Yearly Net Income VS EBIT VS OCF VS FCFMRKR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

MRKR has a Return On Assets of -75.23%. This is in the lower half of the industry: MRKR underperforms 66.97% of its industry peers.
The Return On Equity of MRKR (-88.22%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -75.23%
ROE -88.22%
ROIC N/A
ROA(3y)-61.26%
ROA(5y)-61.64%
ROE(3y)-89.71%
ROE(5y)-93.87%
ROIC(3y)N/A
ROIC(5y)N/A
MRKR Yearly ROA, ROE, ROICMRKR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MRKR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRKR Yearly Profit, Operating, Gross MarginsMRKR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

MRKR has more shares outstanding than it did 1 year ago.
MRKR has more shares outstanding than it did 5 years ago.
MRKR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MRKR Yearly Shares OutstandingMRKR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MRKR Yearly Total Debt VS Total AssetsMRKR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

MRKR has an Altman-Z score of -34.64. This is a bad value and indicates that MRKR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -34.64, MRKR is doing worse than 90.38% of the companies in the same industry.
There is no outstanding debt for MRKR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.64
ROIC/WACCN/A
WACCN/A
MRKR Yearly LT Debt VS Equity VS FCFMRKR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 6.79 indicates that MRKR has no problem at all paying its short term obligations.
With a decent Current ratio value of 6.79, MRKR is doing good in the industry, outperforming 65.70% of the companies in the same industry.
A Quick Ratio of 6.79 indicates that MRKR has no problem at all paying its short term obligations.
MRKR has a Quick ratio of 6.79. This is in the better half of the industry: MRKR outperforms 66.06% of its industry peers.
Industry RankSector Rank
Current Ratio 6.79
Quick Ratio 6.79
MRKR Yearly Current Assets VS Current LiabilitesMRKR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

MRKR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -107.71%.
The Revenue has grown by 71.54% in the past year. This is a very strong growth!
Measured over the past years, MRKR shows a very strong growth in Revenue. The Revenue has been growing by 99.23% on average per year.
EPS 1Y (TTM)-107.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
Revenue 1Y (TTM)71.54%
Revenue growth 3Y74.52%
Revenue growth 5Y99.23%
Sales Q2Q%-71.95%

3.2 Future

MRKR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.91% yearly.
The Revenue is expected to grow by 95.82% on average over the next years. This is a very strong growth
EPS Next Y-104%
EPS Next 2Y-54.27%
EPS Next 3Y-9.15%
EPS Next 5Y29.91%
Revenue Next Year-67.56%
Revenue Next 2Y-41.04%
Revenue Next 3Y49.73%
Revenue Next 5Y95.82%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
MRKR Yearly Revenue VS EstimatesMRKR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
MRKR Yearly EPS VS EstimatesMRKR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRKR. In the last year negative earnings were reported.
Also next year MRKR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRKR Price Earnings VS Forward Price EarningsMRKR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRKR Per share dataMRKR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

MRKR's earnings are expected to decrease with -9.15% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-54.27%
EPS Next 3Y-9.15%

More info and screens

0

5. Dividend

5.1 Amount

MRKR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARKER THERAPEUTICS INC

NASDAQ:MRKR (8/4/2025, 10:00:03 AM)

1.275

-0.08 (-5.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-12 2025-08-12
Inst Owners36.13%
Inst Owner Change0%
Ins Owners2.42%
Ins Owner Change0%
Market Cap14.42M
Analysts84.44
Price Target8.33 (553.33%)
Short Float %0.93%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-29.77%
Min EPS beat(2)-87.59%
Max EPS beat(2)28.04%
EPS beat(4)3
Avg EPS beat(4)4.52%
Min EPS beat(4)-87.59%
Max EPS beat(4)43%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-38.06%
Min Revenue beat(2)-44.56%
Max Revenue beat(2)-31.57%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-24.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.94%
EPS NY rev (1m)12.3%
EPS NY rev (3m)8.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)44.6%
Revenue NY rev (1m)3.85%
Revenue NY rev (3m)-16.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.53
P/FCF N/A
P/OCF N/A
P/B 1
P/tB 1
EV/EBITDA N/A
EPS(TTM)-1.29
EYN/A
EPS(NY)-2.86
Fwd EYN/A
FCF(TTM)-1.11
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS0.5
BVpS1.28
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -75.23%
ROE -88.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.26%
ROA(5y)-61.64%
ROE(3y)-89.71%
ROE(5y)-93.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.79
Quick Ratio 6.79
Altman-Z -34.64
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-107.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
EPS Next Y-104%
EPS Next 2Y-54.27%
EPS Next 3Y-9.15%
EPS Next 5Y29.91%
Revenue 1Y (TTM)71.54%
Revenue growth 3Y74.52%
Revenue growth 5Y99.23%
Sales Q2Q%-71.95%
Revenue Next Year-67.56%
Revenue Next 2Y-41.04%
Revenue Next 3Y49.73%
Revenue Next 5Y95.82%
EBIT growth 1Y0.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3016.25%
EBIT Next 3Y-137.86%
EBIT Next 5Y202.77%
FCF growth 1Y45.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.06%
OCF growth 3YN/A
OCF growth 5YN/A